{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:39:09Z","timestamp":1791819549809,"version":"4.3.4"},"reference-count":56,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["CRD420251113470"],"award-info":[{"award-number":["CRD420251113470"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.neurol.2025.11.005","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:29:17Z","timestamp":1766406557000},"page":"36-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Intranasal insulin for mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4789-6019","authenticated-orcid":false,"given":"A.M.P.","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.R.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.C.N.","family":"Tudella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.V.S.","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.O.M.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2342-9950","authenticated-orcid":false,"given":"L.A.O","family":"Nantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0619-4796","authenticated-orcid":false,"given":"J.V.A.","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.G.","family":"Quiroga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.V.S.","family":"Lima Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.S.","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.S.","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.neurol.2025.11.005_bib0285","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/alz.12362","article-title":"Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020\u20132060)","volume":"17","author":"Rajan","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"10452","key":"10.1016\/j.neurol.2025.11.005_bib0290","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","article-title":"Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission","volume":"404","author":"Livingston","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.neurol.2025.11.005_bib0295","doi-asserted-by":"crossref","first-page":"111","DOI":"10.31887\/DCNS.2009.11.2\/cqiu","article-title":"Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention","volume":"11","author":"Qiu","year":"2009","journal-title":"Dialogues Clin Neurosci"},{"issue":"3","key":"10.1016\/j.neurol.2025.11.005_bib0300","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ni.3102","article-title":"Innate immunity in Alzheimer's disease","volume":"16","author":"Heneka","year":"2015","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.neurol.2025.11.005_bib0305","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer's disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.neurol.2025.11.005_bib0310","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1159\/000330020","article-title":"Vascular risk factors and dementia: 40-year follow-up of a population-based cohort","volume":"31","author":"Ronnemaa","year":"2011","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"12","key":"10.1016\/j.neurol.2025.11.005_bib0315","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1016\/j.febslet.2006.02.067","article-title":"Tau phosphorylation and aggregation in Alzheimer's disease pathology","volume":"580","author":"Avila","year":"2006","journal-title":"FEBS Lett"},{"issue":"11","key":"10.1016\/j.neurol.2025.11.005_bib0320","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1586\/14737175.7.11.1527","article-title":"GSK-3 inhibitors for Alzheimer's disease","volume":"7","author":"Avila","year":"2007","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"10.1016\/j.neurol.2025.11.005_bib0325","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3233\/JAD-180802","article-title":"Understanding the amyloid hypothesis in Alzheimer's disease","volume":"68","author":"Paroni","year":"2019","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"10.1016\/j.neurol.2025.11.005_bib0330","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/joim.12534","article-title":"Insulin signalling in Alzheimer's disease and diabetes: from epidemiology to molecular links","volume":"280","author":"Ribe","year":"2016","journal-title":"J Intern Med"},{"issue":"4","key":"10.1016\/j.neurol.2025.11.005_bib0335","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.nlm.2010.02.002","article-title":"Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance","volume":"93","author":"McNay","year":"2010","journal-title":"Neurobiol Learn Mem"},{"key":"10.1016\/j.neurol.2025.11.005_bib0340","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2147\/NDT.S75546","article-title":"Neuroinflammation in Alzheimer's disease","volume":"11","author":"Zhang","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"10.1016\/j.neurol.2025.11.005_bib0345","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1474-4422(04)00681-7","article-title":"Insulin and neurodegenerative disease: shared and specific mechanisms","volume":"3","author":"Craft","year":"2004","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.neurol.2025.11.005_bib0350","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bbadis.2008.10.014","article-title":"Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease","volume":"1792","author":"Zhao","year":"2009","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10.1016\/j.neurol.2025.11.005_bib0355","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3233\/JAD-2006-9209","article-title":"Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease","volume":"9","author":"de la Monte","year":"2006","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.neurol.2025.11.005_bib0360","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/epirev\/mxn008","article-title":"Dementia of the Alzheimer type","volume":"30","author":"Jalbert","year":"2008","journal-title":"Epidemiol Rev"},{"issue":"5","key":"10.1016\/j.neurol.2025.11.005_bib0365","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.neuron.2008.04.014","article-title":"Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo","volume":"58","author":"Chiu","year":"2008","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.neurol.2025.11.005_bib0370","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1212\/WNL.50.1.164","article-title":"Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype","volume":"50","author":"Craft","year":"1998","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.neurol.2025.11.005_bib0375","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1177\/193229680800200619","article-title":"Alzheimer's disease is type 3 diabetes-evidence reviewed","volume":"2","author":"de la Monte","year":"2008","journal-title":"J Diabetes Sci Technol"},{"issue":"3","key":"10.1016\/j.neurol.2025.11.005_bib0380","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3233\/JAD-2005-8304","article-title":"Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine","volume":"8","author":"Rivera","year":"2005","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.neurol.2025.11.005_bib0385","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40265-016-0674-0","article-title":"Insulin resistance and neurodegeneration: progress towards the development of new therapeutics for Alzheimer's disease","volume":"77","author":"de la Monte","year":"2017","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.neurol.2025.11.005_bib0390","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/156720512799015037","article-title":"Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease","volume":"9","author":"de la Monte","year":"2012","journal-title":"Curr Alzheimer Res"},{"issue":"5","key":"10.1016\/j.neurol.2025.11.005_bib0395","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40266-021-00845-7","article-title":"A phase II, single-center, randomized, double-blind, placebo-controlled study of the safety and therapeutic efficacy of intranasal glulisine in amnestic mild cognitive impairment and probable mild Alzheimer's disease","volume":"38","author":"Rosenbloom","year":"2021","journal-title":"Drugs Aging"},{"issue":"3","key":"10.1016\/j.neurol.2025.11.005_bib0400","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3233\/JAD-141791","article-title":"Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia","volume":"44","author":"Claxton","year":"2015","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.neurol.2025.11.005_bib0405","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3233\/JAD-161256","article-title":"Effects of regular and long-acting insulin on cognition and Alzheimer's disease biomarkers: a pilot clinical trial","volume":"57","author":"Craft","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.neurol.2025.11.005_bib0410","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial","volume":"69","author":"Craft","year":"2012","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2025.11.005_bib0415","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/jcbfm.2014.215","article-title":"Rapid transport within cerebral perivascular spaces underlies widespread tracer distribution in the brain after intranasal administration","volume":"35","author":"Lochhead","year":"2015","journal-title":"J Cereb Blood Flow Metab"},{"issue":"3","key":"10.1016\/j.neurol.2025.11.005_bib0420","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/0196-9781(90)90044-6","article-title":"Insulin binding to brain capillaries is reduced in genetically obese, hyperinsulinemic Zucker rats","volume":"11","author":"Schwartz","year":"1990","journal-title":"Peptides"},{"issue":"9","key":"10.1016\/j.neurol.2025.11.005_bib0425","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamaneurol.2020.1840","article-title":"Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial","volume":"77","author":"Craft","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2025.11.005_bib0430","series-title":"Cochrane handbook for systematic reviews of interventions. 1st ed.","author":"Higgins","year":"2019"},{"key":"10.1016\/j.neurol.2025.11.005_bib0435","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.neurol.2025.11.005_bib0440","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychiatry"},{"issue":"11","key":"10.1016\/j.neurol.2025.11.005_bib0445","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurol.2025.11.005_bib0450","first-page":"31","article-title":"Performance of the dementia severity rating scale: a caregiver questionnaire for rating severity in Alzheimer disease","volume":"10","author":"Clark","year":"1996","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"Suppl. 2","key":"10.1016\/j.neurol.2025.11.005_bib0455","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study","volume":"11","author":"Galasko","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.neurol.2025.11.005_bib0460","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"7414","key":"10.1016\/j.neurol.2025.11.005_bib0465","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.neurol.2025.11.005_bib0470","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Mental Health"},{"issue":"5","key":"10.1016\/j.neurol.2025.11.005_bib0475","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00401-014-1328-5","article-title":"Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies","volume":"128","author":"Yarchoan","year":"2014","journal-title":"Acta Neuropathol"},{"issue":"1 Suppl.","key":"10.1016\/j.neurol.2025.11.005_bib0480","first-page":"S3","article-title":"The paradox of neuronal insulin action and resistance in the development of aging-associated diseases","volume":"10","author":"Steculorum","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurol.2025.11.005_bib0485","doi-asserted-by":"crossref","first-page":"111812","DOI":"10.1016\/j.exger.2022.111812","article-title":"MicroRNA modulation is a potential molecular mechanism for neuroprotective effects of intranasal insulin administration in amyloid betaeta oligomer induced Alzheimer's like rat model","volume":"164","author":"Bazrgar","year":"2022","journal-title":"Exp Gerontol"},{"issue":"7","key":"10.1016\/j.neurol.2025.11.005_bib0490","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.2337\/db14-0568","article-title":"Insulin action in brain regulates systemic metabolism and brain function","volume":"63","author":"Kleinridders","year":"2014","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.neurol.2025.11.005_bib0495","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.neurol.2025.11.005_bib0500","doi-asserted-by":"crossref","first-page":"102348","DOI":"10.1016\/j.arr.2024.102348","article-title":"Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit","volume":"99","author":"Hoilund-Carlsen","year":"2024","journal-title":"Ageing Res Rev"},{"issue":"7","key":"10.1016\/j.neurol.2025.11.005_bib0505","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.3390\/ijms25073892","article-title":"Alzheimer's amyloid hypothesis and antibody therapy: melting glaciers?","volume":"25","author":"Hoilund-Carlsen","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.neurol.2025.11.005_bib0510","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3233\/JAD-220841","article-title":"Amyloid PET: a questionable single primary surrogate efficacy measure on Alzheimer immunotherapy trials","volume":"90","author":"Hoilund-Carlsen","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.neurol.2025.11.005_bib0515","doi-asserted-by":"crossref","first-page":"101996","DOI":"10.1016\/j.arr.2023.101996","article-title":"Passive Alzheimer's immunotherapy: a promising or uncertain option?","volume":"90","author":"Hoilund-Carlsen","year":"2023","journal-title":"Ageing Res Rev"},{"issue":"1","key":"10.1016\/j.neurol.2025.11.005_bib0520","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/13872877251325891","article-title":"The unsafe profile of lecanemab","volume":"105","author":"Hoilund-Carlsen","year":"2025","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"10.1016\/j.neurol.2025.11.005_bib0525","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1093\/brain\/awad159","article-title":"The amyloid cascade hypothesis: an updated critical review","volume":"146","author":"Kepp","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2025.11.005_bib0530","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","article-title":"In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"10.1016\/j.neurol.2025.11.005_bib0535","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neurobiolaging.2005.01.004","article-title":"Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis","volume":"27","author":"Qiu","year":"2006","journal-title":"Neurobiol Aging"},{"issue":"12","key":"10.1016\/j.neurol.2025.11.005_bib0540","doi-asserted-by":"crossref","first-page":"8661","DOI":"10.1002\/alz.14313","article-title":"Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US","volume":"20","author":"Wang","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.neurol.2025.11.005_bib0545","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","article-title":"Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums","volume":"14","author":"Arnold","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2025.11.005_bib0550","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/13872877251329439","article-title":"Semaglutide improves cognitive function and neuroinflammation in APP\/PS1 transgenic mice by activating AMPK and inhibiting TLR4\/NF-\u03baB pathway","volume":"105","author":"Zhai","year":"2025","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.neurol.2025.11.005_bib0555","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1177\/13872877251351329","article-title":"Associations of semaglutide with Alzheimer's disease-related dementias in patients with type 2 diabetes: a real-world target trial emulation study","volume":"106","author":"Wang","year":"2025","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.neurol.2025.11.005_bib0560","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3233\/ADR-200238","article-title":"Dysregulation of insulin-linked metabolic pathways in Alzheimer's disease: co-factor role of apolipoprotein E varepsilon4","volume":"4","author":"Robbins","year":"2020","journal-title":"J Alzheimers Dis Rep"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378725006551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378725006551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T09:42:21Z","timestamp":1770457341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378725006551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":56,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0035378725006551"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2025.11.005","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal insulin for mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2025.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}